

Oguzhan Alagoz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4853174/publications.pdf>

Version: 2024-02-01

95
papers

4,650
citations

109321

35
h-index

110387

64
g-index

100
all docs

100
docs citations

100
times ranked

5361
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalized Disease Screening Decisions Considering a Chronic Condition. <i>Management Science</i> , 2023, 69, 260-282.	4.1	6
2	Breast Cancer Screening Strategies for Women With <i>ATM</i> , <i>CHEK2</i> , and <i>PALB2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2022, 8, 587.	7.1	36
3	A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis. <i>Production and Operations Management</i> , 2022, 31, 2361-2378.	3.8	5
4	Evaluation of different blood pressure assessment strategies and cutoff values to predict postpartum hypertension-related readmissions: a retrospective cohort study. <i>American Journal of Obstetrics & Gynecology</i> MFM, 2021, 3, 100252.	2.6	5
5	Effect of Timing of and Adherence to Social Distancing Measures on COVID-19 Burden in the United States. <i>Annals of Internal Medicine</i> , 2021, 174, 50-57.	3.9	57
6	Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1484-1494.	6.3	92
7	Association of Visitor Contact Precautions With Estimated Hospital-Onset <i>Clostridioides difficile</i> Infection Rates in Acute Care Hospitals. <i>JAMA Network Open</i> , 2021, 4, e210361.	5.9	3
8	Representing Tuberculosis Transmission with Complex Contagion: An Agent-Based Simulation Modeling Approach. <i>Medical Decision Making</i> , 2021, 41, 641-652.	2.4	3
9	Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts. <i>PLoS Computational Biology</i> , 2021, 17, e1009020.	3.2	9
10	The impact of vaccination to control COVID-19 burden in the United States: A simulation modeling approach. <i>PLoS ONE</i> , 2021, 16, e0254456.	2.5	62
11	Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness. <i>Journal of the National Cancer Institute</i> , 2021, , .	6.3	9
12	A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings. <i>Cancer</i> , 2021, 127, 4432-4446.	4.1	7
13	Trade-Offs Between Harms and Benefits of Different Breast Cancer Screening Intervals Among Low-Risk Women. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1017-1026.	6.3	9
14	Long-Term Outcomes and Cost-Effectiveness of Breast Cancer Screening With Digital Breast Tomosynthesis in the United States. <i>Journal of the National Cancer Institute</i> , 2020, 112, 582-589.	6.3	48
15	Skilled Nursing Facility Differences in Readmission Rates by the Diagnosis-Related Group Category of the Initial Hospitalization. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1175-1177.	2.5	0
16	Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation. <i>Annals of Internal Medicine</i> , 2020, 173, 331-341.	3.9	24
17	Evaluation of the Cost-effectiveness of Infection Control Strategies to Reduce Hospital-Onset <i>Clostridioides difficile</i> Infection. <i>JAMA Network Open</i> , 2020, 3, e2012522.	5.9	24
18	Neighborhood disadvantage and 30-day readmission risk following <i>Clostridioides difficile</i> infection hospitalization. <i>BMC Infectious Diseases</i> , 2020, 20, 762.	2.9	7

#	ARTICLE	IF	CITATIONS
19	Reducing C. difficile in children: An agent-based modeling approach to evaluate intervention effectiveness. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 522-530.	1.8	9
20	Benefits and Harms of Mammography Screening for Women With Down Syndrome: a Collaborative Modeling Study. <i>Journal of General Internal Medicine</i> , 2019, 34, 2374-2381.	2.6	6
21	Age-based versus Risk-based Mammography Screening in Women 40-49 Years Old: A Cross-sectional Study. <i>Radiology</i> , 2019, 292, 321-328.	7.3	11
22	Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer. <i>PLoS ONE</i> , 2019, 14, e0217778.	2.5	8
23	Cost-effectiveness of mammography from a publicly funded health care system perspective. <i>CMAJ Open</i> , 2018, 6, E77-E86.	2.4	12
24	Analysis of Mammography Screening Policies under Resource Constraints. <i>Production and Operations Management</i> , 2018, 27, 949-972.	3.8	20
25	Interventions to Reduce the Incidence of Hospital-Onset Clostridium difficile Infection: An Agent-Based Modeling Approach to Evaluate Clinical Effectiveness in Adult Acute Care Hospitals. <i>Clinical Infectious Diseases</i> , 2018, 66, 1192-1203.	5.8	53
26	Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 154.	7.4	209
27	Contribution of Breast Cancer to Overall Mortality for US Women. <i>Medical Decision Making</i> , 2018, 38, 24S-31S.	2.4	22
28	Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models. <i>Medical Decision Making</i> , 2018, 38, 3S-8S.	2.4	31
29	Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49. <i>Medical Decision Making</i> , 2018, 38, 140S-150S.	2.4	13
30	The University of Wisconsin Breast Cancer Epidemiology Simulation Model: An Update. <i>Medical Decision Making</i> , 2018, 38, 99S-111S.	2.4	43
31	Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches. <i>Medical Decision Making</i> , 2018, 38, 126S-139S.	2.4	19
32	Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 229-239.	2.5	4
33	Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 158-164.	2.5	36
34	A New Perspective on Breast Cancer Diagnostic Guidelines to Reduce Overdiagnosis. <i>SSRN Electronic Journal</i> , 2018, , .	0.4	1
35	Preference-sensitive Management of Post-Mammography Decisions in Breast Cancer Diagnosis. <i>Production and Operations Management</i> , 2018, 27, 2313-2338.	3.8	10
36	534. Clostridium difficile Reduction: An Agent-Based Simulation Modeling Approach to Evaluating Intervention Comparative Effectiveness at Pediatric Hospitals. <i>Open Forum Infectious Diseases</i> , 2018, 5, S197-S198.	0.9	0

#	ARTICLE	IF	CITATIONS
37	The effect of mammography screening regimen on incidence-based breast cancer mortality. Journal of Medical Screening, 2018, 25, 197-204.	2.3	7
38	Changes to physician and nurse time burdens when caring for patients under contact precautions. American Journal of Infection Control, 2017, 45, 542-543.	2.3	11
39	Using Collaborative Simulation Modeling to Develop a Web-Based Tool to Support Policy-Level Decision Making About Breast Cancer Screening Initiation Age. MDM Policy and Practice, 2017, 2, 238146831771798.	0.9	8
40	Cost-Effectiveness of Breast Cancer Screening in Turkey, a Developing Country: Results from BahÅŞeÅYehir Mammography Screening Project. The Journal of Breast Health, 2017, 13, 117-122.	1.0	20
41	Costâ€effectiveness of alternative colonoscopy surveillance strategies to mitigate metachronous colorectal cancer incidence. Cancer, 2016, 122, 2560-2570.	4.1	13
42	Using Active Learning for Speeding up Calibration in Simulation Models. Medical Decision Making, 2016, 36, 581-593.	2.4	19
43	Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes. Annals of Internal Medicine, 2016, 165, 700.	3.9	90
44	Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Annals of Internal Medicine, 2016, 164, 215.	3.9	209
45	Heterogeneity in Womenâ€™s Adherence and Its Role in Optimal Breast Cancer Screening Policies. Management Science, 2016, 62, 1339-1362.	4.1	56
46	Cancer Models and Real-world Data: Better Together: Table 1.. Journal of the National Cancer Institute, 2016, 108, djv316.	6.3	12
47	Comparative Effectiveness of Combined Digital Mammography and Tomosynthesis Screening for Women with Dense Breasts. Radiology, 2015, 274, 772-780.	7.3	98
48	Developing a clinical utility framework to evaluate prediction models in radiogenomics. , 2015, 9416, .		3
49	Benefits, Harms, and Cost-Effectiveness of Supplemental Ultrasonography Screening for Women With Dense Breasts. Annals of Internal Medicine, 2015, 162, 157-166.	3.9	175
50	Benefits and Harms of Mammography Screening After Age 74 Years: Model Estimates of Overdiagnosis. Journal of the National Cancer Institute, 2015, 107, djv103-djv103.	6.3	56
51	Developing a utility decision framework to evaluate predictive models in breast cancer risk estimation. Journal of Medical Imaging, 2015, 2, 041005.	1.5	3
52	An Agent-based Simulation Model for <i>Clostridium difficile</i> Infection Control. Medical Decision Making, 2015, 35, 211-229.	2.4	37
53	Clinical outcomes of modelling mammography screening strategies. Health Reports, 2015, 26, 9-15.	0.8	3
54	Modelling mammography screening for breast cancer in the Canadian context: Modification and testing of a microsimulation model. Health Reports, 2015, 26, 3-8.	0.8	4

#	ARTICLE	IF	CITATIONS
55	Total cost-effectiveness of mammography screening strategies. Health Reports, 2015, 26, 16-25.	0.8	20
56	Pursuing optimal thresholds to recommend breast biopsy by quantifying the value of tomosynthesis. , 2014, 9037, 90370U.		3
57	Optimizing Colonoscopy Screening for Colorectal Cancer Prevention and Surveillance. Manufacturing and Service Operations Management, 2014, 16, 381-400.	3.7	68
58	A survey of optimization models on cancer chemotherapy treatment planning. Annals of Operations Research, 2014, 221, 331-356.	4.1	75
59	Effects of Screening and Systemic Adjuvant Therapy on ER-Specific US Breast Cancer Mortality. Journal of the National Cancer Institute, 2014, 106, .	6.3	120
60	Healthcare Intelligence: Turning Data into Knowledge. IEEE Intelligent Systems, 2014, 29, 54-68.	4.0	23
61	Benefits, Harms, and Costs for Breast Cancer Screening After US Implementation of Digital Mammography. Journal of the National Cancer Institute, 2014, 106, dju092.	6.3	120
62	Opportunities for Operations Research in Medical Decision Making. IEEE Intelligent Systems, 2014, 29, 59-62.	4.0	0
63	Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis. Breast Cancer Research and Treatment, 2013, 138, 519-528.	2.5	29
64	A Comprehensive Methodology for Determining the Most Informative Mammographic Features. Journal of Digital Imaging, 2013, 26, 941-947.	2.9	20
65	Optimal Policies for Reducing Unnecessary Follow-Up Mammography Exams in Breast Cancer Diagnosis. Decision Analysis, 2013, 10, 200-224.	2.1	32
66	Cost-Effectiveness of Adjuvant FOLFOX and 5FU/LV Chemotherapy for Patients with Stage II Colon Cancer. Medical Decision Making, 2013, 33, 521-532.	2.4	26
67	A Broader View of Designing the Liver Allocation System. Operations Research, 2012, 60, 757-770.	1.9	63
68	The Effect of Budgetary Restrictions on Breast Cancer Diagnostic Decisions. Manufacturing and Service Operations Management, 2012, 14, 600-617.	3.7	48
69	Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 Years. Annals of Internal Medicine, 2012, 156, 609.	3.9	110
70	State-Transition Modeling. Medical Decision Making, 2012, 32, 690-700.	2.4	231
71	State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Value in Health, 2012, 15, 812-820.	0.3	336
72	OR Forumâ€”A POMDP Approach to Personalize Mammography Screening Decisions. Operations Research, 2012, 60, 1019-1034.	1.9	163

#	ARTICLE	IF	CITATIONS
73	What Is the Optimal Threshold at Which to Recommend Breast Biopsy?. PLoS ONE, 2012, 7, e48820.	2.5	17
74	Medical decision making: open research challenges. IIE Transactions on Healthcare Systems Engineering, 2011, 1, 161-167.	0.8	25
75	Optimizing Cancer Screening Using Partially Observable Markov Decision Processes. , 2011, , 75-89.		3
76	Estimating the Unknown Parameters of the Natural History of Metachronous Colorectal Cancer Using Discrete-Event Simulation. Medical Decision Making, 2011, 31, 611-624.	2.4	21
77	Breast cancer risk estimation with artificial neural networks revisited. Cancer, 2010, 116, 3310-3321.	4.1	103
78	Optimal Breast Biopsy Decision-Making Based on Mammographic Features and Demographic Factors. Operations Research, 2010, 58, 1577-1591.	1.9	94
79	Comparison of Logistic Regression and Artificial Neural Network Models in Breast Cancer Risk Estimation. Radiographics, 2010, 30, 13-22.	3.3	136
80	Markov Decision Processes: A Tool for Sequential Decision Making under Uncertainty. Medical Decision Making, 2010, 30, 474-483.	2.4	187
81	Irreversible treatment decisions under consideration of the research and development pipeline for new therapies. IIE Transactions, 2010, 42, 632-642.	2.1	5
82	Computer-aided diagnostic models in breast cancer screening. Imaging in Medicine, 2010, 2, 313-323.	0.0	45
83	A Logistic Regression Model Based on the National Mammography Database Format to Aid Breast Cancer Diagnosis. American Journal of Roentgenology, 2009, 192, 1117-1127.	2.2	74
84	Probabilistic Computer Model Developed from Clinical Data in National Mammography Database Format to Classify Mammographic Findings. Radiology, 2009, 251, 663-672.	7.3	82
85	Optimizing Organ Allocation and Acceptance. Springer Optimization and Its Applications, 2009, , 1-24.	0.9	16
86	Determining aisle structures for facility designs using a hierarchy of algorithms. IIE Transactions, 2008, 40, 1019-1031.	2.1	11
87	Estimating the Patient's Price of Privacy in Liver Transplantation. Operations Research, 2008, 56, 1393-1410.	1.9	62
88	Choosing Among Living-Donor and Cadaveric Livers. Management Science, 2007, 53, 1702-1715.	4.1	65
89	Determining the Acceptance of Cadaveric Livers Using an Implicit Model of the Waiting List. Operations Research, 2007, 55, 24-36.	1.9	109
90	Incorporating Biological Natural History in Simulation Models: Empirical Estimates of the Progression of End-Stage Liver Disease. Medical Decision Making, 2005, 25, 620-632.	2.4	37

#	ARTICLE	IF	CITATIONS
91	A Clinically Based Discrete-Event Simulation of End-Stage Liver Disease and the Organ Allocation Process. <i>Medical Decision Making</i> , 2005, 25, 199-209.	2.4	98
92	Parallel-machine rescheduling with machine disruptions. <i>IIE Transactions</i> , 2005, 37, 1113-1118.	2.1	27
93	The Optimal Timing of Living-Donor Liver Transplantation. <i>Management Science</i> , 2004, 50, 1420-1430.	4.1	162
94	Preference-Sensitive Management of Post-Mammography Decisions in Breast Cancer Diagnosis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
95	Optimal breast cancer risk reduction policies tailored to personal risk level. <i>Health Care Management Science</i> , 0, , .	2.6	0